Evox Therapeutics is a biotechnology company developing exosome therapeutics using exosomes, cell-derived vesicles, to deliver small and large molecule therapeutics. The company is headquartered in Oxford, Oxfordshire, United Kingdom and was founded in 2016 by Per Lundin.
The company has a proprietary technology to modify exosomes to target specific organs such as the brain and central nervous system.Evox Therapeutics has built an intellectual property portfolio encompassing key aspects of extracellular vesicle-based nucleic acid and protein delivery technology.
Funding
Series A
On May 16, 2016 Evox Therapeutics completed their series A funding round with £10 in funding from Oxford Sciences Innovation.
Series B
On September 2, 2018 Evox Therapeutics completed their series B funding round with £35 in funding from Redmile Group (lead investor), Panacea Venture, Oxford University Innovation, Oxford Sciences Innovation, GV, Cowen Healthcare Investments, and Borealis Ventures.
Grant - Duchenne UK
On November 13, 2018 Evox therapeutics was awarded in grant from Duchenne UK worth £655 thousand.
Grant - Innovative UK
On March 22, 2019 Evox Therapeutics was awarded a grant from Innovative UK worth £1.5 million.
Timeline
Grant - Innovative UK
On March 22, 2019 Evox Therapeutics was awarded a grant from Innovative UK worth £1.5 million.
Grant - Duchenne UK
On November 13, 2018 Evox therapeutics was awarded in grant from Duchenne UK worth £655 thousand.
Series B funding round
On September 2, 2018 Evox Therapeutics completed their series B funding round with £35 in funding from Redmile Group (lead investor), Panacea Venture, Oxford University Innovation, Oxford Sciences Innovation, GV, Cowen Healthcare Investments, and Borealis Ventures.
Series A funding round
On May 16, 2016 Evox Therapeutics completed their series A funding round with £10 in funding from Oxford Sciences Innovation.
People
Further reading
Duchenne UK Awards £655K to Evox Therapeutics to Develop New Way of Gene Therapy Delivery
Vijaya Iyer
Web
Evox Therapeutics Named in The Sunday Times Fast Track Disruptors to Watch
Evox Therapeutics
Web
Evox Therapeutics secures £35.5m Series B - Oxford University Innovation
Innovative UK
Web
Documentaries, videos and podcasts
Duchenne UK and Evox Therapeutics, An interview with Professor Matthew Wood
November 13, 2018
LSX World Congress 2019 Presentations - Evox Therapeutics
February 12, 2019
Companies
References
Evox Therapeutics
Company
United Kingdom
Oxfordshire
Therapeutics
Related Topics
OSI (Oxford Sciences Innovation)An investment company founded in 2015 that specializes in spin-outs from Oxford University’s Math, Physical, Life Sciences, Medical Sciences, Computer Sciences and Engineering divisions. OSI supplies financial and human capital to help market ideas.
BiotechnologyBiolotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.
